Search research articles
Contact Us
Filters
Showing results (1-10 of 27) with videos related to
Page
of 3
Sort By:
Therapeutic Advances in Neurological Disorders
|
December 25, 2010
What are the Therapeutic Advances in Neurology? Opinions from World Experts
Gordon Mallarkey
Drug and Therapeutics Bulletin
|
March 26, 2026
Providing reliable drug information in a changing regulatory landscape
Gordon Mallarkey
Drugs in Context
|
May 1, 2018
Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
Edgardo Kaplinsky, Gordon Mallarkey
The Journal of International Medical Research
|
May 17, 2022
What we are doing to help researchers publish their papers in our journal
Gordon Mallarkey, Matthew Thorne
Therapeutic Advances in Medical Oncology
|
February 17, 2017
European Society for Medical Oncology Copenhagen update: potential practice-changing findings
Gordon Mallarkey, Axel Grothey
Therapeutic Advances in Medical Oncology
|
July 4, 2012
Pathways and biomarkers in breast cancer: latest evidence
Gordon Mallarkey, R Charles Coombes
Therapeutic Advances in Medical Oncology
|
January 17, 2013
Targeted therapies in medical oncology: successes, failures and next steps
Gordon Mallarkey, R Charles Coombes
Therapeutic Advances in Chronic Disease
|
December 20, 2012
Looking at the causes of, and possible treatments for, psychiatric diseases: gene-environment interactions, circadian rhythms and neuronal dysfunction
Gordon Mallarkey, Philip B Mitchell
Therapeutic Advances in Musculoskeletal Disease
|
February 3, 2016
Osteoporosis therapeutics: recent developments at ASBMR
Gordon Mallarkey, David M Reid
The Medical Journal of Australia
|
April 21, 2009
Liaison between public hospital staff and the pharmaceutical industry: guidance from the NSW Therapeutic Advisory Group
Diana H Shipp, Gordon Mallarkey
Page
of 3
Search research articles
Search
Showing results (1-10 of 27) with videos related to
Sort By:
Page
of 3
Therapeutic Advances in Neurological Disorders
|
December 25, 2010
What are the Therapeutic Advances in Neurology? Opinions from World Experts
Gordon Mallarkey
Drug and Therapeutics Bulletin
|
March 26, 2026
Providing reliable drug information in a changing regulatory landscape
Gordon Mallarkey
Drugs in Context
|
May 1, 2018
Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil
Edgardo Kaplinsky, Gordon Mallarkey
The Journal of International Medical Research
|
May 17, 2022
What we are doing to help researchers publish their papers in our journal
Gordon Mallarkey, Matthew Thorne
Therapeutic Advances in Medical Oncology
|
February 17, 2017
European Society for Medical Oncology Copenhagen update: potential practice-changing findings
Gordon Mallarkey, Axel Grothey
Therapeutic Advances in Medical Oncology
|
July 4, 2012
Pathways and biomarkers in breast cancer: latest evidence
Gordon Mallarkey, R Charles Coombes
Therapeutic Advances in Medical Oncology
|
January 17, 2013
Targeted therapies in medical oncology: successes, failures and next steps
Gordon Mallarkey, R Charles Coombes
Therapeutic Advances in Chronic Disease
|
December 20, 2012
Looking at the causes of, and possible treatments for, psychiatric diseases: gene-environment interactions, circadian rhythms and neuronal dysfunction
Gordon Mallarkey, Philip B Mitchell
Therapeutic Advances in Musculoskeletal Disease
|
February 3, 2016
Osteoporosis therapeutics: recent developments at ASBMR
Gordon Mallarkey, David M Reid
The Medical Journal of Australia
|
April 21, 2009
Liaison between public hospital staff and the pharmaceutical industry: guidance from the NSW Therapeutic Advisory Group
Diana H Shipp, Gordon Mallarkey
Page
of 3